Phase I/II Study of Pentostatin Combined With Tacrolimus and Mini-Methotrexate for GVHD Prevention After MUD BMT

This study has been completed.
Sponsor:
Collaborator:
Astex Pharmaceuticals
Information provided by (Responsible Party):
M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:
NCT00506922
First received: July 20, 2007
Last updated: August 1, 2012
Last verified: August 2012

July 20, 2007
August 1, 2012
September 2000
November 2009   (final data collection date for primary outcome measure)
Number of Patients Without GVHD at 100 Days [ Time Frame: 100 days ] [ Designated as safety issue: Yes ]
The primary efficacy endpoint of escalating doses Pentostatin with Tacrolimus + Methotrexate is success, defined to be that the patient is alive, engrafted, and without acute graft-versus-host disease (GVHD) at 100 days.
Not Provided
Complete list of historical versions of study NCT00506922 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Phase I/II Study of Pentostatin Combined With Tacrolimus and Mini-Methotrexate for GVHD Prevention After MUD BMT
Phase I/II Study of Pentostatin Combined With Tacrolimus and Mini-Methotrexate for GVHD Prevention After Matched-Unrelated Donor Blood and Marrow Transplantation

Primary Objective:

1. To determine efficacy of escalating doses of pentostatin in combination with tacrolimus and methotrexate for the prevention of acute graft-versus-host disease (GVHD) in the context of unrelated donor and one antigen mismatched related donor transplantation.

Secondary Objectives:

  1. To determine safety of escalating doses of pentostatin in combination with tacrolimus and methotrexate.
  2. To reduce the incidence of acute GVHD following transplants with unrelated donor to 40%.
  3. To document blood levels of tacrolimus when combined with pentostatin.

During the study, patients will have blood, urine, bone marrow, and X-ray exams done. These exams are done to monitor the results of the transplantation. Blood tests will be done daily while patients are hospitalized.

Patients in this study will receive chemotherapy and/or radiation to treat their malignancy and prevent graft rejection. This is given before the infusion of donor cells.

Patients with myeloid leukemias may receive busulfan by vein (IV) for 4 days and cyclophosphamide by vein for 2 days.

Patients with lymphoid malignancies may receive thiotepa by vein in one dose, cyclophosphamide by vein for 2 days, and irradiation for 4 days.

Other chemotherapy treatments may be used before donor cell infusion.

IV injections will be given through a previously inserted catheter that extends into the vena cava (a large chest vein).

Patients will be randomly picked (as in the toss of a coin) to receive one of five different treatments. This is done to learn the benefit of pentostatin treatment and the appropriate dose. Four of the treatments will use different dose schedules of pentostatin. The fifth treatment group will receive no pentostatin at all. All patients receive tacrolimus and methotrexate.

Pentostatin will be given by vein in 4 doses during the first month after transplant. Tacrolimus (FK506) will be given by vein or mouth for 6 months. Methotrexate will be given by vein for 3 doses in the first week after transplant.

Patients will receive blood and platelet transfusions after the transplant. The number of transfusions will depend on how quickly the blood cell counts return to a normal range.

Patients will remain in the hospital for about 4-6 weeks and in the Houston area for 100 days after the transplant.

This is an investigational study. All of the study drugs are commercially available. Pentostatin will not be used for GVHD prevention outside of this study. A total of 150 patients will take part in this study.

Interventional
Phase 1
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Leukemia
  • Lymphoma
  • Drug: Pentostatin

    Given intravenously on days +8, +15, +22 and +30 post transplant:

    Group 2 - Pentostatin 0.5 mg/m^2

    Group 3 - Pentostatin 1 mg/m^2

    Group 4 - Pentostatin 1.5 mg/m^2

    Group 5 - Pentostatin 2 mg/m^2

    Other Names:
    • Nipent
    • Deoxycoformycin
    • DCF
  • Drug: Tacrolimus
    Given intravenously from day -2, and will be switched to oral dosing when tolerated.
    Other Name: Prograf
  • Drug: Methotrexate
    Given intravenously on days +1, +3, and +6 at the dose of 5 mg/m2.
  • Experimental: No Pentostatin
    Group 1: No Pentostatin
    Interventions:
    • Drug: Pentostatin
    • Drug: Tacrolimus
    • Drug: Methotrexate
  • Experimental: Pentostatin 0.5
    Group 2: Pentostatin 0.5 mg/m^2
    Interventions:
    • Drug: Pentostatin
    • Drug: Tacrolimus
    • Drug: Methotrexate
  • Experimental: Pentostatin 1
    Group 3: Pentostatin 1 mg/m^2
    Interventions:
    • Drug: Pentostatin
    • Drug: Tacrolimus
    • Drug: Methotrexate
  • Experimental: Pentostatin 1.5
    Group 4: Pentostatin 1.5 mg/m^2
    Interventions:
    • Drug: Pentostatin
    • Drug: Tacrolimus
    • Drug: Methotrexate
  • Experimental: Pentostatin 2
    Group 5: Pentostatin 2 mg/m^2
    Interventions:
    • Drug: Pentostatin
    • Drug: Tacrolimus
    • Drug: Methotrexate
Parmar S, Del Lima M, Zou Y, Patah PA, Liu P, Cano P, Rondon G, Pesoa S, de Padua Silva L, Qazilbash MH, Hosing C, Popat U, Kebriaei P, Shpall EJ, Giralt S, Champlin RE, Stastny P, Fernandez-Vina M. Donor-recipient mismatches in MHC class I chain-related gene A in unrelated donor transplantation lead to increased incidence of acute graft-versus-host disease. Blood. 2009 Oct 1;114(14):2884-7. Epub 2009 Aug 4.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
150
November 2009
November 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Patients receiving allogeneic hematopoietic transplants from an unrelated donor or one antigen mismatched related donors.
  2. Patients with AML, ALL, Hodgkin's disease, MDS (including CMML), CML in late chronic or accelerated phase or in blast crisis, and lymphoma in first or later relapses.
  3. Patients must have bilirubin < 1.5 mg/dL, DLCO > 50% predicted, LVEF > 45% and performance status 0 or 1.
  4. Candidates must have a creatinine level < 1.5 mg/dL or a calculated creatinine clearance > 60 ml/min.

Exclusion Criteria:

  1. HIV seropositivity
  2. Uncontrolled infection
  3. Pregnancy
  4. Candidates should not have received chemotherapy other than hydroxyurea or Gleevec for at least 3 weeks prior to treatment. Maintenance therapy with oral chemotherapy is acceptable. Treatment day is defined as transplant day +8, which is the date of first dose of pentostatin.
  5. Diagnosis of myelofibrosis.
Both
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00506922
ID00-132
No
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Astex Pharmaceuticals
Principal Investigator: Marcos de Lima, MD M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
August 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP